Inotuzumab Ozogamicin and Low-Intensity Chemotherapy in Older Patients With Newly Diagnosed CD22 + Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia.

MLA

Chevallier, Patrice, et al. “Inotuzumab Ozogamicin and Low-Intensity Chemotherapy in Older Patients With Newly Diagnosed CD22 + Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, Oct. 2024, p. JCO2400490. EBSCOhost, https://doi.org/10.1200/JCO.24.00490.

APA

Chevallier, P., Leguay, T., Delord, M., Salek, C., Kim, R., Huguet, F., Hicheri, Y., Wartiovaara-Kautto, U., Raffoux, E., Cluzeau, T., Balsat, M., Roth-Guepin, G., Tavernier, E., Lepretre, S., Bilger, K., Bergugnat, H., Berceanu, A., Alexis, M., Doubek, M., … Rousselot, P. (2024). Inotuzumab Ozogamicin and Low-Intensity Chemotherapy in Older Patients With Newly Diagnosed CD22 + Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO2400490. https://doi.org/10.1200/JCO.24.00490

Chicago

Chevallier, Patrice, Thibaut Leguay, Marc Delord, Cyril Salek, Rathana Kim, Françoise Huguet, Yosr Hicheri, et al. 2024. “Inotuzumab Ozogamicin and Low-Intensity Chemotherapy in Older Patients With Newly Diagnosed CD22 + Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, October, JCO2400490. doi:10.1200/JCO.24.00490.